<DOC>
	<DOC>NCT00259090</DOC>
	<brief_summary>To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.</brief_summary>
	<brief_title>Anti-tumour Effects &amp; Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal women. Biopsy confirmation of primary breast cancer. Oestrogen receptor positive tumour. Fit for surgery within one month. Written informed consent to participate in the study Previous treatment with any antihormonal therapy for breast cancer. Previous radiotherapy to the primary tumour. Previous chemotherapy for the primary tumour.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>